You are here

Kymriah

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Fierce Pharma

Bristol Myers Squibb

Flag link:

ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits

ASH: Novartis makes its Kymriah case in follicular lymphoma, but another Gilead showdown awaits

Fierce Pharma

follicular lymphoma

clinical trials

Flag link:

Novartis says CAR-T cancer therapy works in second lymphoma type

Novartis says CAR-T cancer therapy works in second lymphoma type

BioPharma Dive

follicular lymphoma

Flag link:

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

Pharmaforum

follicular lymphoma

regenerative medicine

Flag link:

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients

Fierce Pharma

Flag link:

Novartis still hasn't solved its lingering CAR-T manufacturing issues

Novartis still hasn't solved its lingering CAR-T manufacturing issues

Biopharma Dive

drug manufacturing

Flag link:

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Pharmaceutical Business Review

Flag link:

Celgene posts pivotal CAR-T data ahead of FDA filing

Celgene posts pivotal CAR-T data ahead of FDA filing

Fierce Biotech

Flag link:

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Yahoo/Reuters

Flag link:

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Endpoints

Flag link:

Medicare would cover CAR-T cell therapies under new CMS proposal

Medicare would cover CAR-T cell therapies under new CMS proposal

Marketwatch

Gilead Sciences

Flag link:

Oncology round-up: CAR-T conference raises hopes for solid tumour therapy

Oncology round-up: CAR-T conference raises hopes for solid tumour therapy

Pharmaforum

Flag link:

Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company

Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company

Fierce Pharma

diffuse large B-cell lymphoma

Gilead Sciences

Flag link:

Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy

Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy

BioSpace

Flag link:

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Fierce Pharma

Flag link:

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

Xconomy

Gilead Sciences

Flag link:

Novartis seeks to acquire French CAR-T contract manufacturer

Novartis seeks to acquire French CAR-T contract manufacturer

Biopharma Dive

Flag link:

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Fierce Pharma

drug manufacturing

Flag link:

2 Sets of Disasters Biotech Will Pay For in 2019

2 Sets of Disasters Biotech Will Pay For in 2019

Yahoo/Motley Fool

Gilead Sciences

Spark Therapeutics

Flag link:

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

Fierce Pharma

Flag link:

Pages